Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Santen Pharmaceutical Co ( (JP:4536) ) has shared an announcement.
Santen Pharmaceutical Co., Ltd. announced the status of its share buyback program, repurchasing 2,772,000 common shares for a total of 4,508,303,950 yen between September 1 and September 30, 2025. This buyback is part of a broader plan approved by the Board of Directors to repurchase up to 19,800,000 shares, reflecting the company’s strategic financial management and potential impact on shareholder value.
The most recent analyst rating on (JP:4536) stock is a Buy with a Yen2600.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company dedicated to eye health, providing products and services to patients, consumers, and medical professionals globally. With over 130 years of experience, Santen focuses on the research, development, manufacturing, and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries.
Average Trading Volume: 1,409,416
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen556.4B
For an in-depth examination of 4536 stock, go to TipRanks’ Overview page.